Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer

S. C. Hopkins, G. M. Palmieri, H. B. Niell, M. Moinuddin, M. S. Soloway

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

Original languageEnglish
Pages (from-to)117-121
Number of pages5
JournalCancer
Volume53
Issue number1
StatePublished - Mar 1 1984

Fingerprint

Hydroxyproline
Prostatic Neoplasms
Bone and Bones
Bone Remodeling
Bone Development
Radionuclide Imaging
Disease Progression
Urine
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hopkins, S. C., Palmieri, G. M., Niell, H. B., Moinuddin, M., & Soloway, M. S. (1984). Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer. Cancer, 53(1), 117-121.

Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer. / Hopkins, S. C.; Palmieri, G. M.; Niell, H. B.; Moinuddin, M.; Soloway, M. S.

In: Cancer, Vol. 53, No. 1, 01.03.1984, p. 117-121.

Research output: Contribution to journalArticle

Hopkins, SC, Palmieri, GM, Niell, HB, Moinuddin, M & Soloway, MS 1984, 'Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer', Cancer, vol. 53, no. 1, pp. 117-121.
Hopkins SC, Palmieri GM, Niell HB, Moinuddin M, Soloway MS. Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer. Cancer. 1984 Mar 1;53(1):117-121.
Hopkins, S. C. ; Palmieri, G. M. ; Niell, H. B. ; Moinuddin, M. ; Soloway, M. S. / Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer. In: Cancer. 1984 ; Vol. 53, No. 1. pp. 117-121.
@article{fe3baebcca484a10ad7ef86d6ed98760,
title = "Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer",
abstract = "Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90{\%} of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.",
author = "Hopkins, {S. C.} and Palmieri, {G. M.} and Niell, {H. B.} and M. Moinuddin and Soloway, {M. S.}",
year = "1984",
month = "3",
day = "1",
language = "English",
volume = "53",
pages = "117--121",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer

AU - Hopkins, S. C.

AU - Palmieri, G. M.

AU - Niell, H. B.

AU - Moinuddin, M.

AU - Soloway, M. S.

PY - 1984/3/1

Y1 - 1984/3/1

N2 - Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

AB - Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

UR - http://www.scopus.com/inward/record.url?scp=0021353141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021353141&partnerID=8YFLogxK

M3 - Article

C2 - 6689994

AN - SCOPUS:0021353141

VL - 53

SP - 117

EP - 121

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -